Abstract
Pharmacologic reperfusion with fibrinolytic therapy remains the principal method of infarct-artery recanalization for patients with acute myocardial infarction (AMI). Its universal availability, ease of administration, and effectiveness have been demonstrated in an impressive array of clinical trials in the last two decades (1–3). Nevertheless, significant limitations and unfulfilled expectations continue to render this therapy less than perfect. Three generations of fibrinolytic agents have not been able to solve three vexing problems: restoration of normal flow [Thrombolysis in Myocardial Infarction (TIMI) grade 3] in the infarct artery is achieved in fewer than half the patients at 60 min from drug administration: one-fourth of those with epicardial reperfusion have impaired microvascular perfusion (4,5); and finally, major bleeding [particularly intracranial hemorrhage (ICH)] remains high and has a major impact on outcome. Three recent megatrials (6–8) comparing the parent tissue plasminogen activator (t-PA) molecule with novel compounds, specifically designed to address some of t-PA’s deficiencies, have failed to demonstrate, in general, superior efficacy (mortality reduction) or safety (ICH reduction). Some progress has been made with respect to major, nonintracranial, hemorrhage (9) and treatment of patients presenting beyond 4 h from symptom onset (8).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
GISSI Investigators. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet 1986;1:397–401.
ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet 1992;339:753–770.
GUSTO-I Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673–682.
Lincoff AM, Topol EJ. Illusion of reperfusion. Does anyone achieve optimal reperfusion during acute myocardial infarction? [corrected and republished article originally printed in Circulation 1993;87: 1792–1805]. Circulation 1993;88:1361–1374.
Ito H, Okamura A, Iwakura K, et al. Myocardial perfusion patterns related to thrombolysis in myocardial infarction perfusion grades after coronary angioplasty in patients with acute anterior wall myocardial infarction. Circulation 1996;93:1993–1999.
The GUSTO III Investigators. A comparison of reteplase and alteplase for acute myocardial infarction. N Engl J Med 1997;337:1118–1123.
INTIME-II Investigators. Intravenous n-PA for the treatment of infarcting myocardium early. InTIME-II, a double-blind comparison of single-bolus lanoteplase vs accelerated alteplase for the treatment of patients with acute myocardial infarction. Eur Heart J 2000;21:2005–2013.
Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999;354:716–722.
Lesaffre E, Bluhmki E, Wang-Clow F, et al. The general concepts of an equivalence trial, applied to ASSENT-2, a large-scale mortality study comparing two fibrinolytic agents in acute myocardial infarction. Eur Heart J 2001;22:898–902.
Weinberger I, Fuchs J, Davidson E, Rotenberg Z. Circulating aggregated platelets, number of platelets per aggregate, and platelet size during acute myocardial infarction. Am J Cardiol 1992;70:981–983.
Topol EJ. Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence. Circulation 1998;97:211–218.
Coller B, Folts J, Smith S, Scudder L, Jordan R. Abolition of in vivo platelet thrombus formation in primates with monoclonal antibodies to the platelet GPIIb/IIIa receptor (correlation with bleeding time, platelet aggregation, and blockade of GPIIb/IIIa receptors). Circulation 1989;80:1766–1774.
Gold HK, Garabedian HD, Dinsmore RE, et al. Restoration of coronary flow in myocardial infarction by intravenous chimeric 7E3 antibody without exogenous plasminogen activators. Observations in animals and humans. Circulation 1997;95:1755–1759.
Kleiman NS, Ohman ME, Califf RM, et al. Profound inhibition of platelet aggregation with monoclonal antibody 7E3 fab after thrombolytic therapy. Results of the thrombolysis and angioplasty in myocardial infarction (TAMI) 8 pilot study. J Am Coll Cardiol 1993;22:381–389.
Ohman EM, Kleiman NS, Gacioch G, et al., for the IMPACT-AMI Investigators. Combined accelerated tissue-plasminogen activator and platelet glycoprotein IIb/IIIa integrin receptor blockade with Integrilin in acute myocardial infarction. Results of a randomized, placebo-controlled, dose-ranging trial. Circulation 1997;95:846–854.
Ronner E, van Kesteren HA, Zijnen P, et al. Safety and efficacy of eptifibatide vs placebo in patients receiving thrombolytic therapy with streptokinase for acute myocardial infarction. A phase II dose escalation, randomized, double-blind study. Eur Heart J 2000;21:1530–1536.
The PURSUIT Trial Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 1998;339:436–443.
PARADIGM Investigators. Combining thrombolysis with the platelet glycoprotein IIb/IIIa inhibitor lamifiban: results of the Platelet Aggregation Receptor Antagonist Dose Investigation and Reperfusion Gain in Myocardial Infarction (PARADIGM) trial. J Am Coll Cardiol 1998;32:2003–2010.
Antman EM, Giugliano RP, Gibson CM, et al. Abciximab facilitates the rate and extent of thrombolysis: results of the thrombolysis in myocardial infarction (TIMI) 14 trial. The TIMI 14 Investigators. Circulation 1999;99:2720–2732.
The SPEED Investigators. Trial of abciximab with and without low-dose reteplase for acute myocardial infarction. Strategies for Patency Enhancement in the Emergency Department (SPEED) Group. Circulation 2000;101:2788–2794.
Brener SJ, Zeymer U, Adgey AAJ, et al. Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the INtegrilin and low-dose ThRombolysis in Acute Myocardial Infarction-INTRO AMI Trial. J Am Coll Cardiol 2002;39:377–386.
Giugliano RP, Roe MT, Zeymer U, et al. Restoration of epicardial and myocardial perfusion in acute ST-elevation myocardial infarction with combination eptifibatide+reduced-dose tenecteplase: dose-finding results from the INTEGRITI trial. Circulation 2001,104:II-538 (abstract).
Antman EM, Louwerenburg HW, Baars HF, et al., for the ENTIRE-TIMI 23 Investigators. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) Trial. Circulation 2002;105:1642–1649.
Gibson CM, Cannon CP, Murphy SA, et al. Relationship of TIMI myocardial perfusion grade to mortality after administration of thrombolytic drugs. Circulation 2000;101:125–130.
Chesebro J, Knatterud G, Roberts R, et al. Thrombolysis in Myocardial Infarction (TIMI) Trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge. Circulation 1987;76:142–154.
Herrmann HC, Moliterno DJ, Ohman EM, et al. Facilitation of early percutaneous coronary intervention after reteplase with or without abciximab in acute myocardial infarction: results from the SPEED (GUSTO4 pilot) trial. J Am Coll Cardiol 2000;36:1489–1496.
Schweiger MJ, Cannon CP, Murphy SA, et al. Early coronary intervention following pharmacologic therapy for acute myocardial infarction (the combined TIMI 10B-TIMI 14 experience). Am J Cardiol 2001;88:831–836.
Ellis S, Van de Werf F, Ribeiro-daSilva E, Topol E. Present status of rescue coronary angioplasty: current polarization of opinion and randomized trials. J Am Coll Cardiol 1992;19:681–686.
Abbottsmith CW, Topol EJ, George BS, et al. Fate of patients with acute myocardial infarction with patency of the infarct-related vessel achieved with successful thrombolysis versus rescue angioplasty. J Am Coll Cardiol 1990;16:770–778.
Ellis SG, Da Silva ER, Spaulding CM, Nobuyoshi M, Weiner B, Talley JD. Review of immediate angioplasty after fibrinolytic therapy for acute myocardial infarction: insights from the RESCUE I, RESCUE II, and other contemporary clinical experiences. Am Heart J 2000;139:1046–1053.
GUSTO V Investigators. Reperfusion therapy for acute myocardial infarction with fibrinolytic therapy or combination reduced fibrinolytic therapy and platelet glycoprotein IIb/IIIa inhibition: the GUSTO V randomised trial. Lancet 2001;357:1905–1914.
Barbash GI, Birnbaum Y, Bogaerts K, et al. Treatment of reinfarction after thrombolytic therapy for acute myocardial infarction : an analysis of outcome and treatment choices in the Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries (GUSTO I) and Assessment of the Safety of a New Thrombolytic (ASSENT 2) Studies. Circulation 2001;103:954–960.
Lincoff AM, Califf RM, Van De Werf F, et al. Mortality at 1 year with combination platelet glycoprotein IIb/IIIa inhibition and reduced-dose fibrinolytic therapy vs conventional fibrinolytic therapy for acute myocardial infarction: GUSTO V randomized trial. JAMA 2002;288:2130–2135.
ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomized trial in acute myocardial infarction. Lancet 2001;358:605–613.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Springer Science+Business Media New York
About this chapter
Cite this chapter
Brener, S.J. (2003). Glycoprotein IIb/IIIa Receptor Blockade in Acute Myocardial Infarction. In: Lincoff, A.M. (eds) Platelet Glycoprotein IIb/IIIa Inhibitors in Cardiovascular Disease. Contemporary Cardiology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-376-7_13
Download citation
DOI: https://doi.org/10.1007/978-1-59259-376-7_13
Publisher Name: Humana Press, Totowa, NJ
Print ISBN: 978-1-61737-408-1
Online ISBN: 978-1-59259-376-7
eBook Packages: Springer Book Archive